Last reviewed · How we verify

NCT05787795: DREAM

Identifying and Characterizing Preclinical MS

Recruiting now Last updated 14 November 2025
What this trial tests

trial testing biological samples in Multiple Sclerosis in 1,000 participants. Currently enrolling.

Timeline
21 June 2022
Primary endpoint
30 June 2032
30 June 2033

Quick facts

Lead sponsorYale University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date21 June 2022
Primary completion30 June 2032
Estimated completion30 June 2033
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Yale University

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to try and identify risk factors and biologic changes that suggest that someone may go on to develop multiple sclerosis before a person has shown any symptoms of the disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of biological samples

Trials testing the same drug.

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Yale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05787795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing